Valuation: 3SBio Inc.

Capitalization 51.77B 58.64B 7.5B 6.32B 5.77B 5.51B 10.23B 680B 10.58B 67.01B 26.65B 327B 28.13B 27.55B 1,143B P/E ratio 2025 *
5.29x
P/E ratio 2026 * 15.6x
Enterprise value 41.97B 47.54B 6.08B 5.13B 4.68B 4.46B 8.29B 551B 8.57B 54.33B 21.61B 265B 22.81B 22.34B 927B EV / Sales 2025 *
2.28x
EV / Sales 2026 * 3.38x
Free-Float
72.15%
Yield 2025 *
3.82%
Yield 2026 * 2.39%
1 day-2.82%
1 week-0.17%
Current month+0.60%
1 month-15.26%
3 months-19.67%
6 months-23.10%
Current year-3.06%
1 week 22.4
Extreme 22.4
24.74
1 month 22.3
Extreme 22.3
29.3
Current year 22.3
Extreme 22.3
29.3
1 year 6.35
Extreme 6.35
36.8
3 years 4.91
Extreme 4.91
36.8
5 years 4.72
Extreme 4.72
36.8
10 years 4.72
Extreme 4.72
36.8
Manager TitleAgeSince
Chief Executive Officer 63 2005-12-31
Director of Finance/CFO - 2023-07-02
Corporate Officer/Principal 56 2014-11-26
Director TitleAgeSince
Chairman 63 2012-04-02
Director/Board Member 56 2012-06-10
Director/Board Member 57 2015-05-31
Change 5d. change 1-year change 3-years change Capi.($)
-2.82%-0.17%+269.13%+178.38% 7.71B
+1.26%+3.18%+19.15%+3.54% 79.94B
+3.67%+2.05%+43.79%+249.37% 59.51B
-6.88%-16.24%-40.77%-50.10% 56.08B
+0.41%+71.90%+71.90%+71.90% 54.71B
+2.27%+5.38%+46.39%-32.75% 28.06B
-0.67%+10.42%+148.05%+108.06% 19.9B
+2.94%-0.83%+47.59%+27.26% 19.67B
-3.38%-4.38%+27.98%-77.21% 15.83B
+0.59%+6.10%+28.07%+67.93% 15.86B
Average -0.28%+1.45%+66.13%+54.64% 35.73B
Weighted average by Cap. -0.02%-0.05%+38.99%+53.87%

Financials

2025 *2026 *
Net sales 18.44B 20.89B 2.67B 2.25B 2.06B 1.96B 3.64B 242B 3.77B 23.88B 9.49B 117B 10.02B 9.82B 407B 11.49B 13.01B 1.66B 1.4B 1.28B 1.22B 2.27B 151B 2.35B 14.87B 5.91B 72.65B 6.24B 6.11B 254B
Net income 9.59B 10.86B 1.39B 1.17B 1.07B 1.02B 1.89B 126B 1.96B 12.41B 4.94B 60.64B 5.21B 5.1B 212B 3.26B 3.69B 473M 398M 363M 347M 644M 42.81B 666M 4.22B 1.68B 20.63B 1.77B 1.74B 72.03B
Net Debt -9.79B -11.09B -1.42B -1.2B -1.09B -1.04B -1.93B -129B -2B -12.68B -5.04B -61.94B -5.32B -5.21B -216B -12.98B -14.7B -1.88B -1.59B -1.45B -1.38B -2.56B -170B -2.65B -16.8B -6.68B -82.1B -7.05B -6.91B -287B
Logo 3SBio Inc.
3SBio Inc is an investment holding company mainly engaged in the development, production, marketing and sale of pharmaceutical products. The Company’s core products include several biopharmaceutical drugs, TPIAO, recombinant human erythropoietin(rhEPO) products, with brand of EPIAO and SEPO, Yisaipu, Cipterbin and a small molecule drug, Mandi and tumor necrosis factor (TNF). Through its subsidiaries, the Company is engaged in project management and consultation. The Company still engages in developing innovative biological products, including mAbs, bi-specific antibodies and fusion proteins, and a number of small molecule drugs, both innovative and generic, in the areas of nephrology, oncology, auto-immune and inflammatory diseases, ophthalmology and dermatological diseases. The Company distributes its products within the domestic market and to overseas markets.
Employees
6,268
Date Price Change Volume
26-02-12 23.44 $ -2.82% 13,848,075
26-02-11 24.12 $ -1.55% 11,101,170
26-02-10 24.50 $ +4.26% 24,013,480
26-02-09 23.50 $ +2.44% 9,099,428
26-02-06 22.94 $ -0.78% 12,237,060
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
20.69CNY
Average target price
34.72CNY
Spread / Average Target
+67.76%

Quarterly revenue - Rate of surprise